 Amanda Wieland
Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 6 | 2021 | 246 | 1.670 |
Why?
| | Liver Transplantation | 2 | 2018 | 830 | 0.740 |
Why?
| | Hypertension, Portal | 1 | 2021 | 62 | 0.730 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2018 | 85 | 0.580 |
Why?
| | Hepatitis C | 1 | 2018 | 229 | 0.500 |
Why?
| | Dysbiosis | 1 | 2015 | 146 | 0.460 |
Why?
| | Diabetes Complications | 1 | 2015 | 212 | 0.430 |
Why?
| | Specialization | 1 | 2013 | 117 | 0.410 |
Why?
| | Hepatitis C, Chronic | 3 | 2021 | 152 | 0.410 |
Why?
| | Intestines | 1 | 2015 | 325 | 0.410 |
Why?
| | Physicians, Primary Care | 2 | 2018 | 222 | 0.390 |
Why?
| | Fatty Liver | 1 | 2013 | 217 | 0.380 |
Why?
| | Patient Education as Topic | 1 | 2015 | 685 | 0.350 |
Why?
| | Hepacivirus | 4 | 2021 | 234 | 0.340 |
Why?
| | Disease Management | 1 | 2013 | 563 | 0.330 |
Why?
| | Antiviral Agents | 3 | 2021 | 651 | 0.320 |
Why?
| | Microbiota | 1 | 2015 | 652 | 0.310 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1193 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1182 | 0.250 |
Why?
| | Obesity | 2 | 2021 | 2523 | 0.230 |
Why?
| | Simeprevir | 2 | 2017 | 9 | 0.180 |
Why?
| | Interferons | 1 | 2021 | 152 | 0.180 |
Why?
| | Sofosbuvir | 2 | 2017 | 54 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 181 | 0.170 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 240 | 0.170 |
Why?
| | T-Lymphocyte Subsets | 1 | 2021 | 383 | 0.160 |
Why?
| | Waiting Lists | 1 | 2018 | 223 | 0.140 |
Why?
| | Protease Inhibitors | 1 | 2017 | 102 | 0.140 |
Why?
| | Drug Costs | 1 | 2017 | 91 | 0.140 |
Why?
| | Transcriptome | 1 | 2021 | 742 | 0.130 |
Why?
| | Drug Interactions | 1 | 2017 | 347 | 0.130 |
Why?
| | Risk Factors | 4 | 2021 | 8715 | 0.130 |
Why?
| | Metagenome | 1 | 2015 | 122 | 0.120 |
Why?
| | Humans | 11 | 2021 | 115859 | 0.120 |
Why?
| | Models, Animal | 1 | 2015 | 350 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 4673 | 0.100 |
Why?
| | Education, Medical, Continuing | 1 | 2013 | 119 | 0.100 |
Why?
| | Prevalence | 2 | 2021 | 2270 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2365 | 0.100 |
Why?
| | Body Mass Index | 2 | 2021 | 1974 | 0.100 |
Why?
| | Data Collection | 1 | 2013 | 637 | 0.090 |
Why?
| | United States | 2 | 2018 | 12319 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2018 | 9163 | 0.090 |
Why?
| | Female | 6 | 2018 | 60070 | 0.080 |
Why?
| | Middle Aged | 4 | 2017 | 27078 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2015 | 1078 | 0.070 |
Why?
| | Male | 6 | 2021 | 56103 | 0.070 |
Why?
| | Adult | 3 | 2017 | 30814 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 962 | 0.060 |
Why?
| | Aged | 2 | 2017 | 19292 | 0.040 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 33 | 0.040 |
Why?
| | Models, Economic | 1 | 2017 | 48 | 0.040 |
Why?
| | Pharmacy | 1 | 2017 | 29 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2017 | 79 | 0.030 |
Why?
| | Remission Induction | 1 | 2017 | 240 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 428 | 0.030 |
Why?
| | Ribavirin | 1 | 2017 | 89 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 157 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1359 | 0.030 |
Why?
| | Pharmacists | 1 | 2017 | 237 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 548 | 0.030 |
Why?
| | Weight Loss | 1 | 2018 | 633 | 0.030 |
Why?
| | Animals | 1 | 2015 | 32158 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1830 | 0.030 |
Why?
| | Biomarkers | 1 | 2021 | 3474 | 0.020 |
Why?
| | Liver | 1 | 2018 | 1693 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6276 | 0.020 |
Why?
| | Primary Health Care | 1 | 2018 | 1520 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4122 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2017 | 12615 | 0.010 |
Why?
|
|
Wieland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|